Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Medivir AB    MVIR B   SE0000273294

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Medivir AB : Medivir: Simeprevir data from COSMOS study in Hepatitis C patients will be presented as late-breaking presentation at AASLD

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/07/2013 | 02:53pm CEST

Regulatory News:

Medivir AB (OMX: MVIR) announced that data from the phase IIa COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) of the investigational protease inhibitor simeprevir (TMC435) administered once daily with Gilead's investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease has been accepted as a late-breaking oral presentation at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). AASLD will take place November 1 to 5 in Washington, D.C.

The COSMOS data will be presented during the late-breaking oral session on Monday, November 4, 2:45-4:30 p.m. (EST) in Hall E: SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study.

· Lead Author: Ira M. Jacobson, Weill Cornell Medical College, New York, USA

Full session details and data presentation listings for the 2013 AASLD Annual Meeting can be found at http://www.aasld.org/livermeeting.

About Simeprevir

Simeprevir is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, for the treatment of genotype 1 and genotype 4 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells.

Janssen is responsible for the global clinical development of simeprevir and has acquired exclusive, worldwide marketing rights, except for in the Nordic countries. Medivir will retain marketing rights for simeprevir in these countries.

Simeprevir was approved in Japan in September 2013 for the treatment of genotype 1 hepatitis C. In the U.S., the New Drug Application (NDA) filed by Janssen for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients was granted Priority Review designation by the Food and Drug Administration (FDA) in May. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C.

To date, more than 3,700 patients have been treated with simeprevir in clinical trials. Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

For additional information about simeprevir clinical trials, please visit www.clinicaltrials.gov.

About Sofosbuvir

Sofosbuvir (formerly referred to as GS-7977) is a once-daily nucleotide analog polymerase inhibitor for the treatment of HCV infection being developed by Gilead Sciences, Inc. Sofosbuvir is being evaluated as part of multiple therapeutic regimens, including programs with RBV alone and in combination with peg-IFN and RBV.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company's website: www.medivir.com

This information was brought to you by Cision http://news.cision.com

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR Mobile:
+46 708 537 292.


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVIR AB
10/13 MEDIVIR : Remetinostat phase II data demonstrate efficacy on skin lesions, reduc..
10/05 MEDIVIR : Announces Positive Topline Results from Phase IIa Osteoarthritis Study..
10/05 MEDIVIR : AMR Centre deal with Medivir targets superbug time-bomb
09/25 MEDIVIR : announces positive topline results from phase IIa osteoarthritis study..
09/21 MEDIVIR : Data Monitoring Committee Gives 'Go Ahead' in the MIV-711 Osteoarthrit..
09/14 MEDIVIR : Data monitoring committee gives "Go Ahead" in the MIV-711 osteoarthrit..
09/11 MEDIVIR : announces Janssen to discontinue development of JNJ-4178 for hepatitis..
08/24 MEDIVIR : Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis
08/18 MEDIVIR : initiates clinical study of birinapant in combination with KEYTRUDA® (..
08/18 MEDIVIR : licenses exclusive rights to MIV-802 for Greater China to Ascletis
More news
News from SeekingAlpha
09/27 Medivir (MVRBY) Announces Topline Results From Phase 2A Osteoarthritis Study ..
08/18 Medivir launches study of birinapant/Keytruda combo in treatment-resistant tu..
08/18 Medivir out-licenses HCV candidate MIV-802 to Ascletis in Greater China
08/16 Medivir on go to start U.S. clinical development of osteoarthritis candidate ..
07/25 Medivir ABB reports 1H results
Financials ( SEK)
Sales 2017 48,0 M
EBIT 2017 -360 M
Net income 2017 -354 M
Finance 2017 464 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 18,5x
EV / Sales 2018 21,9x
Capitalization 1 354 M
Chart MEDIVIR AB
Duration : Period :
Medivir AB Technical Analysis Chart | MVIR B | SE0000273294 | 4-Traders
Technical analysis trends MEDIVIR AB
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Average target price 75,0  SEK
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
Christine Lind President & Chief Executive Officer
Anna Yvonne Monica Malm Bernsten Chairman
Richard Bethell Chief Scientific Officer
John Öhd Chief Medical Officer
Daniel Eriksson Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVIR AB-28.57%167
GILEAD SCIENCES11.65%104 409
REGENERON PHARMACEUTICALS20.67%47 756
VERTEX PHARMACEUTICALS107.56%39 003
ACTELION23.24%29 757
GENMAB22.08%13 881